Business
Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12
– Company to Host Conference Call on March 12, 2026, at 4:30 p.m. ET – SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a
About this update from Capricor Therapeutics, Inc.
[{"type":"text","content":"– Company to Host Conference Call on March 12, 2026, at 4:30 p.m. ET – SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2025, after the market close on Thursday, March 12, 2026. Management will host a conference call and webcast at 4:30 p.m. ET that same day. Title:Capricor Therapeutics Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update Conference Call and Webcast Date:Thursday, March 12, 2026 Time:4:30 p.m. ET Call Details:Toll-Free: 1-800-717-1738International: 1-646-307-1865Conference ID: 70035Participants may dial in using the numbers above and ask to be joined to the call or click the Call me™ link for instant telephone access to the event. Webcast:Webcast – Click Here A replay of the webcast will be available shortly after the conclusion of the live event and will be accessible in the Investors section of the Company’s website at www.capricor.com. About Capricor Therapeutics Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, Deramiocel, an allogeneic cardiac-derived cell therapy that is currently in late-stage development for the treatment of Duchenne muscular dystrophy (DMD). Extensive preclinical and clinical data have demonstrated Deramiocel’s potent immunomodulatory and anti-fibrotic effects in helping to preserve cardiac and skeletal muscle function in DMD. Capricor is also leveraging the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on vaccinology and the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics, with the potential to treat and prevent a wide range of diseases. At Capricor, we are committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and X. Cautionary Note Regarding ...